Podcast 12 Dec 2025Tackling pulmonary fibrosis: Boehringer Ingelheim’s new drug + AI approach In this episode we sit down with Martin Beck, Senior Vice President and Head of the Inflammation Business Unit at Boehringer Ingelheim. December 12, 2025 Share WhatsApp Twitter Linkedin Email Listen Now Apple Music Spotify More
In Depth 3 Dec 2025 Boehringer Ingelheim’s pipeline activity: A busy year of dealmaking for the German pharma in 2025 Discover Boehringer Ingelheim’s pipeline focus areas and how its dealmaking in 2025 has expanded its therapeutic arsenal. December 3, 2025 - 11 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 12 Sep 2024New treatments being developed for schizophrenia Explore the latest strides in schizophrenia treatment development as 2024 heralds a pivotal year, with promising collaborations and trials. September 12, 2024 Share WhatsApp Twitter Linkedin Email
News and Trends 22 Jun 2023 FDA approves type 2 diabetes drug for children 10 and older The U.S. Food and Drug Administration (FDA) has approved Jardiance (empagliflozin) 10 mg and 25 mg tablets to lower blood sugar along with diet and exercise in children 10 years and older with type 2 diabetes, Boehringer Ingelheim and Eli Lilly and Company have announced. “As the burden of type 2 diabetes increases among young […] June 22, 2023 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Apr 2023 RetinAI and Boehringer Ingelheim to use AI to develop treatment for geographic atrophy RetinAI Medical AG, which creates clinical and imaging data management software and advanced analytics using artificial intelligence (AI) for ophthalmology, is partnering with Boehringer Ingelheim. The companies aim to improve patient outcomes in geographic atrophy (GA) by combining RetinAI’s Discovery platform and AI tools with Boehringer Ingelheim’s research in retinal diseases. GA is a progressive, […] April 21, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 9 Mar 2023 5 advancements in kidney disease research over the past year Prevalent in millions of people across the globe, kidney diseases manifest through various symptoms like blood and excess protein in urine, fluid retention causing swollen ankles, poor appetite and even the inability of the body to filter waste, resulting in acute kidney failure. To boost the research and development of treatments for kidney diseases, Kidney […] March 9, 2023 - 7 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jan 2023 Boehringer Ingelheim and 3T Biosciences to develop next-generation cancer immunotherapies Boehringer Ingelheim and 3T Biosciences have entered into a strategic collaboration and licensing agreement to discover and develop next-generation cancer therapies to address high unmet patient needs. The partnership will bring together 3T Biosciences’ best-in-class 3T-TRACE (T-Cell Receptor Antigen and Cross-Reactivity Engine) discovery platform with Boehringer Ingelheim’s two-pronged research strategy combining cancer cell-directed and immune […] January 9, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 2 Sep 2022 Psoriasis pustules disappear in over half of patients using Boehringer Ingelheim drug More than half of patients treated for psoriasis with an intravenous injection showed no visible pustules just one week after receiving treatment. Boehringer Ingelheim announced today (September 2) that the U.S. Food and Drug Administration (FDA) has approved the first treatment option, SPEVIGO, for generalized pustular psoriasis (GPP) flares in adults. SPEVIGO is a novel, […] September 2, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 11 May 2021 ADC Approval Buoys Spirits in Cancer Treatment Space The FDA recently approved an antibody-drug conjugate drug from ADC Therapeutics as a treatment for blood cancer. This has given a major confidence boost to other European companies in the field as the deal mill picks up speed. Last month, ADC Therapeutics in Switzerland broke into the mainstream when its lead candidate Zynlonta received FDA […] May 11, 2021 - 7 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 16 Jul 2019 Boehringer Ingelheim Acquires Cancer Vaccine Biotech in €325M Deal The German giant Boehringer Ingelheim has acquired the Swiss company AMAL Therapeutics and its cancer vaccine technology in a deal worth up to €325M. The deal includes €225M in upfront and developmental milestone payments, as well as up to €100M in undisclosed commercial milestone payments. AMAL’s vaccine development pipeline includes five preclinical programs. The lead […] July 16, 2019 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 13 Sep 2018 Boehringer Ingelheim Acquires Oncolytic Virus Biotech Company Boehringer Ingelheim is paying €210M to acquire all the remaining shares of ViraTherapeutics, an Austrian biotech company developing oncolytic viral therapies for cancer. ViraTherapeutics develops cancer therapies based on viruses that selectively kill tumor cells, based on the principle that cancer cells show defective mechanisms to defend themselves against viruses that are not able to […] September 13, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 5 Apr 2018 Boehringer Offers €1Bn for New Checkpoint Inhibitor from a French Biotech OSE Immunotherapeutics could receive up to €1.1Bn from its new partner Boehringer Ingelheim, which has set its eyes on a new type of checkpoint inhibitor being developed by the French biotech. OSE Immunotherapeutics has entered a global license and collaboration deal with Boehringer Ingelheim for the development of OSE-172, a checkpoint inhibitor antibody to treat […] April 5, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email